Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612948 · ClinicalTrials.gov registry record · Phase 4
Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients
A Phase 4 study, sponsored by University of Tennessee Graduate School of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 82
- Enrollment target
NCT02612948 is a Phase 4 study that has completed, run by University of Tennessee Graduate School of Medicine. The registered enrollment target is 82 participants.
The verdict
NCT02612948, a Phase 4 study, has completed, sponsored by University of Tennessee Graduate School of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 82 participants
- Enrollment target
Study Summary
Scheduled, low-dose quetiapine is effective in preventing delirium in high-risk critically ill, trauma/surgical patients. Prophylaxis also reduced ventilator duration and ICU length of stay.
Interventions
- DRUG Quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2013-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02612948
The ClinicalTrials.gov registry entry for NCT02612948 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Tennessee Graduate School of Medicine, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quetiapine is the first listed.
NCT02612948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02612948 about?
NCT02612948 is a clinical study titled "Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients". Scheduled, low-dose quetiapine is effective in preventing delirium in high-risk critically ill, trauma/surgical patients. Prophylaxis also reduced ventilator duration and ICU length of stay.
What is the current status of trial NCT02612948?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 82 participants. The study started on 2013-11. Estimated completion is 2014-06.
What interventions are being tested in trial NCT02612948?
The interventions under investigation include: Quetiapine (DRUG).
Who is sponsoring clinical trial NCT02612948?
This trial is sponsored by University of Tennessee Graduate School of Medicine, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.